2025 H2 -tulosraportti
160 päivää sitten
‧38 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 min sittenFA Forum. "Thor Medical ASA itself refers to a market for targeted radiopharmaceutical treatments which is estimated to grow to $15 billion by 2030 and $28 billion by 2034. Thor is now in the innermost circle with gigantic market potential.💰💰 Thor Medical ASA plans the next production phases AlphaTwo and AlphaGlobal to scale up capacity after AlphaOne at Herøya. [1] Planned phases and factories AlphaTwo (medium term): Planned for potential operation in the second half of 2029 with a capacity 8 to 10 times larger than AlphaOne. AlphaGlobal (long term): A future vision for global industrialization with the goal of delivering over 1 million patient doses by 2035. Management has confirmed that they will achieve 40-50% profit on all contracts, because Thor does not have particularly strong competition. Therefore, Thor Medical ASA is in a unique position. I sincerely hope that they do not get acquired. But builds up production as agreed with the Alpha Two factory (8-10 times larger than Alpha One ...in the short term and the Alpha Global factory in the long term.
·10 min sittenFrom Investtech Monday (August 3) after the rise on Friday: Thor Medical ASA rose sharply by 28.1 percent and closed at 5.79 kroner. The last time the stock rose as sharply was November 22, 2024, when it was up 42.9 percent. The stock has thus risen seven of the last nine days. The stock has thus risen 33.1 percent since the buy signal from an inverse head-and-shoulders formation seven days ago. There was also very high turnover. In total, approximately 127 million kroner were traded in the stock, which is 39 times the usual daily turnover. Thor Medical is a producer and supplier of alpha particle emitters for cancer treatment. The production process is based on the separation of naturally occurring radioactive decay products from thorium (Th-232). The production process is based on a new technology developed by Thor Medical that combines high efficiency and competitive cost structure with the best environmental friendliness in its class. All chemicals and radioactive materials are recycled and reused; therefore, the process produces very little waste. The process extracts only the radioactivity that occurs naturally in thorium, and therefore requires no irradiation in nuclear reactors or expensive accelerators. Since the source is thorium, which decays with a half-life of 14 billion years, we can produce continuously and provide a reliable supply of the sought-after alpha particle emitters.
·25 min sittenSo the first milestone is just behind us. One delivers on date, and before the 3rd quarter has passed. First delivery already made. Now one is just waiting for the big news, that the first major user of Thorium for cancer treatment places an order. That's when it shoots up. It can quickly reach 6-8 kroner with today's situation, but will shoot up upon order. How high? 20-30-40 kroner? An order might be closer than one suspects. Thor has been in China some time ago!!
·28 min sittenNow I believe most short-term investors have sold their shares to more long-term hands. Then we can perhaps expect a stabilization around today's price or a possible increase.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
160 päivää sitten
‧38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 min sittenFA Forum. "Thor Medical ASA itself refers to a market for targeted radiopharmaceutical treatments which is estimated to grow to $15 billion by 2030 and $28 billion by 2034. Thor is now in the innermost circle with gigantic market potential.💰💰 Thor Medical ASA plans the next production phases AlphaTwo and AlphaGlobal to scale up capacity after AlphaOne at Herøya. [1] Planned phases and factories AlphaTwo (medium term): Planned for potential operation in the second half of 2029 with a capacity 8 to 10 times larger than AlphaOne. AlphaGlobal (long term): A future vision for global industrialization with the goal of delivering over 1 million patient doses by 2035. Management has confirmed that they will achieve 40-50% profit on all contracts, because Thor does not have particularly strong competition. Therefore, Thor Medical ASA is in a unique position. I sincerely hope that they do not get acquired. But builds up production as agreed with the Alpha Two factory (8-10 times larger than Alpha One ...in the short term and the Alpha Global factory in the long term.
- ·10 min sittenFrom Investtech Monday (August 3) after the rise on Friday: Thor Medical ASA rose sharply by 28.1 percent and closed at 5.79 kroner. The last time the stock rose as sharply was November 22, 2024, when it was up 42.9 percent. The stock has thus risen seven of the last nine days. The stock has thus risen 33.1 percent since the buy signal from an inverse head-and-shoulders formation seven days ago. There was also very high turnover. In total, approximately 127 million kroner were traded in the stock, which is 39 times the usual daily turnover. Thor Medical is a producer and supplier of alpha particle emitters for cancer treatment. The production process is based on the separation of naturally occurring radioactive decay products from thorium (Th-232). The production process is based on a new technology developed by Thor Medical that combines high efficiency and competitive cost structure with the best environmental friendliness in its class. All chemicals and radioactive materials are recycled and reused; therefore, the process produces very little waste. The process extracts only the radioactivity that occurs naturally in thorium, and therefore requires no irradiation in nuclear reactors or expensive accelerators. Since the source is thorium, which decays with a half-life of 14 billion years, we can produce continuously and provide a reliable supply of the sought-after alpha particle emitters.
- ·25 min sittenSo the first milestone is just behind us. One delivers on date, and before the 3rd quarter has passed. First delivery already made. Now one is just waiting for the big news, that the first major user of Thorium for cancer treatment places an order. That's when it shoots up. It can quickly reach 6-8 kroner with today's situation, but will shoot up upon order. How high? 20-30-40 kroner? An order might be closer than one suspects. Thor has been in China some time ago!!
- ·28 min sittenNow I believe most short-term investors have sold their shares to more long-term hands. Then we can perhaps expect a stabilization around today's price or a possible increase.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
2025 H2 -tulosraportti
160 päivää sitten
‧38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 min sittenFA Forum. "Thor Medical ASA itself refers to a market for targeted radiopharmaceutical treatments which is estimated to grow to $15 billion by 2030 and $28 billion by 2034. Thor is now in the innermost circle with gigantic market potential.💰💰 Thor Medical ASA plans the next production phases AlphaTwo and AlphaGlobal to scale up capacity after AlphaOne at Herøya. [1] Planned phases and factories AlphaTwo (medium term): Planned for potential operation in the second half of 2029 with a capacity 8 to 10 times larger than AlphaOne. AlphaGlobal (long term): A future vision for global industrialization with the goal of delivering over 1 million patient doses by 2035. Management has confirmed that they will achieve 40-50% profit on all contracts, because Thor does not have particularly strong competition. Therefore, Thor Medical ASA is in a unique position. I sincerely hope that they do not get acquired. But builds up production as agreed with the Alpha Two factory (8-10 times larger than Alpha One ...in the short term and the Alpha Global factory in the long term.
- ·10 min sittenFrom Investtech Monday (August 3) after the rise on Friday: Thor Medical ASA rose sharply by 28.1 percent and closed at 5.79 kroner. The last time the stock rose as sharply was November 22, 2024, when it was up 42.9 percent. The stock has thus risen seven of the last nine days. The stock has thus risen 33.1 percent since the buy signal from an inverse head-and-shoulders formation seven days ago. There was also very high turnover. In total, approximately 127 million kroner were traded in the stock, which is 39 times the usual daily turnover. Thor Medical is a producer and supplier of alpha particle emitters for cancer treatment. The production process is based on the separation of naturally occurring radioactive decay products from thorium (Th-232). The production process is based on a new technology developed by Thor Medical that combines high efficiency and competitive cost structure with the best environmental friendliness in its class. All chemicals and radioactive materials are recycled and reused; therefore, the process produces very little waste. The process extracts only the radioactivity that occurs naturally in thorium, and therefore requires no irradiation in nuclear reactors or expensive accelerators. Since the source is thorium, which decays with a half-life of 14 billion years, we can produce continuously and provide a reliable supply of the sought-after alpha particle emitters.
- ·25 min sittenSo the first milestone is just behind us. One delivers on date, and before the 3rd quarter has passed. First delivery already made. Now one is just waiting for the big news, that the first major user of Thorium for cancer treatment places an order. That's when it shoots up. It can quickly reach 6-8 kroner with today's situation, but will shoot up upon order. How high? 20-30-40 kroner? An order might be closer than one suspects. Thor has been in China some time ago!!
- ·28 min sittenNow I believe most short-term investors have sold their shares to more long-term hands. Then we can perhaps expect a stabilization around today's price or a possible increase.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt